Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLST
The updated ALLSTAR analysis demonstrated sustained benefit of Durvalumab for OS and PFS, as well as a possible long-term benefit of radiation dose escalation > 66 Gy on LC.
Authors
- Alexandra Hochreiter (ORCID: https://orcid.org/0000-0003-4526-6091)
- Claudia Steffal
- Karin Dieckmann (ORCID: https://orcid.org/0000-0002-5311-2976)
- Heidi Stranzl
- Petra Feurstein
- Elvis Ruznic (ORCID: https://orcid.org/0000-0001-7686-1008)
- Brane Grambozov (ORCID: https://orcid.org/0000-0003-2454-7425)
- Danijela Minasch
- Brigitte Langer
- Franz Zehentmayr (ORCID: https://orcid.org/0000-0001-5931-3907)
- Barbara Breitfelder
- Karoline Kirchhammer
- Marisa Klebermass
- Falk Röder (ORCID: https://orcid.org/0009-0004-7549-0785)
- Georg B. Gruber
- Ayurzana Purevdorj (ORCID: https://orcid.org/0009-0002-2071-381X)
Institutions
- Innsbruck Medical University (AT)
- Medical University of Graz (AT)
- Paracelsus Medical University (AT)
- Klinikum Klagenfurt (AT)
- Klinik Hietzing (AT)
- Comprehensive Cancer Center Vienna (AT)
- Kepler Universitätsklinikum (AT)
- Universitätsklinikum Krems (AT)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3390/cancers17091443
- Citations
- 3
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- AstraZeneca
- Salzburger Landesregierung